NCT02374736 - Effect of Privigen Against Graft Loss | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

March 9, 2018

Study Completion Date

May 9, 2019

Conditions

Kidney Transplantation

Interventions

DRUG

Privigen (Human normal immunoglobulin G (IgG > 98 % purity))

"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."

Trial Locations (1)

75010

Service de Néphrologie et transplantation rénale - HU Saint-Louis, Paris